MedCity News
DECEMBER 26, 2023
AstraZeneca is paying $1 billion up front to acquire Gracell Biotechnologies, a clinical-stage cell therapy developer. The deal is the latest in a series of AstraZeneca moves intended to expand its presence in the burgeoning cell therapy field.
European Pharmaceutical Review
DECEMBER 26, 2023
The number of approved gene therapies for the treatment of monogenetic disorders and diseases has increased in recent years, reflecting the field’s rapid advances and the development of revolutionary new technologies and techniques. The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 26, 2023
By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
Pharmaceutical Technology
DECEMBER 26, 2023
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 26, 2023
In looking ahead to 2024, the healthcare industry stands at the cusp of a transformative era of transparency. With impending regulatory changes and growing consumer empowerment, the landscape is poised for continued meaningful progress.
Spotio
DECEMBER 26, 2023
Manufacturing sales is anything but simple. Fortunately, it’s far from impossible. You just need to implement an effective manufacturing sales strategy to meet your company’s revenue goals. We can help you with that! Once you equip your sales team with the strategy and technology they need to close deals, they’ll do so at a consistent clip.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Evolve Your Success
DECEMBER 26, 2023
There is a myth that medical sales are very hard to get into, but if you put the time and effort into this program, you will get the job that you want. This is what Joseph “Joey” Hutchison learned from his successful journey in medical sales. After going through the Medical Sales Career Builder program, he was able to break into trauma med sales in just three months.
MedCity News
DECEMBER 26, 2023
Hospitals and hospital systems need to make clearer and more consistent demands for climate accountability from their suppliers, and they need to follow through with preferred green vendor programs and the like.
Rep-Lite
DECEMBER 26, 2023
Recruiting medical staff, including non-clinical roles such as device equipment specialists, department managers, or medical sales representatives, involves several complexities due to the unique nature of the healthcare industry. Medical sales staff recruitment firms may face challenges such as finding the right talent, ensuring compliance, incorporating innovation, and others.
PharmExec
DECEMBER 26, 2023
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
DECEMBER 26, 2023
AstraZeneca agrees a $1.
Pharmaceutical Technology
DECEMBER 26, 2023
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Commerce
DECEMBER 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
Pharmaceutical Technology
DECEMBER 26, 2023
Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmExec
DECEMBER 26, 2023
Five trends in pharmaceutical marketing from the past year.
Pharmaceutical Technology
DECEMBER 26, 2023
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
PharmaTech
DECEMBER 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
Pharmaceutical Technology
DECEMBER 26, 2023
AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Sarcomas.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
MedCity News
DECEMBER 26, 2023
Ambreen Molitor, Planned Parenthood’s national director of venture and innovation, discussed three partnerships her organization has launched this year to address barriers to abortion care. These partnerships tackle barriers such as cost, changing state laws and lack of emotional support.
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC).
Pharmaceutical Technology
DECEMBER 26, 2023
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
Pharmaceutical Technology
DECEMBER 26, 2023
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
111 
Let's personalize your content